More Data Needed To Assess Sinovac Jabs: Experts

"); jQuery("#212 h3").html("

Related News Programmes

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1570127_1_20210113184624.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1570127-20210113.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1570127-20210113.htm', 'DCS.dcsqry', '' ); } } }); }); });

2021-01-13 HKT 11:31

Share this story

facebook

  • Medical experts say the data available so far on the efficacy of the Sinovac coronavirus jabs must be interpreted carefully. File image: Shutterstock

    Medical experts say the data available so far on the efficacy of the Sinovac coronavirus jabs must be interpreted carefully. File image: Shutterstock

Medical experts on Wednesday said more data is needed to evaluate the efficacy of the coronavirus vaccine produced by mainland company Sinovac, in view of media reports that the jabs were found to be 50 percent effective during trials in Brazil.

Infectious disease specialist Joseph Tsang from Hong Kong Medical Association said the data released so far was preliminary and incomplete, and should be interpreted carefully.

"According to the media, the 50.4 per cent efficacy rate includes patients with mild symptoms and those asymptomatic carriers. So whether the asymptomatic carriers bring down the figures, we don't know at this point. So we have to get more data from Sinovac in order to interpret as a whole," he said.

Tsang said he also hoped to see more data collected from other countries which have used Sinovac vaccines, rather than just Brazil.

A specialist in respiratory medicine, Dr Leung Chi-chiu, said the figures available currently cannot be used to make apple-to-apple comparisons between coronavirus vaccines produced by different companies.

"We are not certain what these figures are talking about. There are multiple levels of efficacy. We can talk about efficacy against all infections. We can talk about efficacy against symptomatic infections. We can talk about efficacy against serious infections. All these have different meanings," he said.

"We need to look at the full data set before we can have a better guess of the actual situation and compare the efficacy between different vaccines," Leung said.

The Secretary for the Civil Service, Patrick Nip, meanwhile, said an expert panel appointed by the government would meet this week and review relevant clinical data.

Nip, who is one of the officials in charge of the vaccination programme to be rolled out in Hong Kong, said the panel would give clear advice on the matter later.

It is expected that Hong Kong people will start receiving coronavirus vaccinations in mid-February, with jabs produced by Sinovac being the first to arrive in the city.

RECENT NEWS

ZA Bank Brings Nasdaq Data To Hong Kong, Expanding US Stock Access And Investor Education

ZA Bank and Nasdaq have announced a collaboration aimed at enhancing digital wealth management in Hong Kong and interna... Read more

Hong Kong To Study One‑Stop Infrastructure For Equities, Bonds And Digital Assets

The Hong Kong Monetary Authority’s (HKMA) CMU OmniClear and the Hong Kong Exchange (HKEX) are set to begin a study on... Read more

Hong Kong To Issue First Stablecoin Licenses In March, Expand Crypto Regulation

Hong Kong will issue its first licenses for fiat-referenced stablecoin issuers in March and introduce new legislation l... Read more

MSIG Joins US$6B IFC Credit Insurance Facility To Boost Emerging Market Lending

MSIG USA and Mitsui Sumitomo Insurance (MSI Japan), together referred to as MSIG, have joined a new insurance-ba... Read more

Why The $2 Trillion Stablecoin Prediction Is Too Low

McKinsey estimates the stablecoin market will hit $2 trillion by 2028. But according to Sam Lin, COO of dtcpay, even th... Read more

RedotPay Eyes US IPO With Potential US$1 Billion Raise

RedotPay is reportedly exploring an IPO in the US that could raise more than US$1 billion, according to people famili... Read more